762: Jeremy Skillington of Poolbeg Pharma: AI partner has completed build & optimisation of its RSV human challenge data

8:02
 
مشاركة
 

Manage episode 332683695 series 2936804
بواسطة Vox Markets Podcast، اكتشفه Player FM ومجتمعنا ـ حقوق الطبع والنشر مملوكة للناشر وليس لـPlayer FM، والصوت يبث مباشرة من خوادمه. اضغط زر الاشتراك لمتابعة التحديثات في Player FM، أو ألصق رابط التغذية الراجعة في أي تطبيق بودكاست آخر.
Jeremy Skillington CEO of Poolbeg Pharma #POLB discusses how their Artificial Intelligence partner OneThree Biotech, Inc., has completed the build and optimisation of a tailored AI model of Poolbeg's Respiratory Syncytial Virus human challenge data and can now commence its analysis, with results expected in Q4 2022.
Highlights:

• Build and optimisation phase of AI model to identify RSV drug targets and treatments completed - results expected in Q4 2022
• Model is uniquely tailored to use Poolbeg's human challenge trial data of RSV
• The Directors believe this is the first time that AI analysis has been used to identify new drug targets and treatments for RSV using human challenge trial data
• Process will identify novel drug targets and treatments quicker and in a more cost-efficient manner than previously possible
To read full RNS click HERE

851 حلقات